Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes

International Journal of Antimicrobial Agents

Volumn 18, Issue 5, 2001, Pages 419-425

  Hand, W Lee ^a   Hand, Debra L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antibiotic interactions with human PMN; Azithromycin; Intracelluar uptake of antibiotic

Indexed keywords

2,4 DINITROPHENOL; ADENOSINE; AMMONIUM CHLORIDE; AZITHROMYCIN; CATALASE; CEPHALOSPORIN; CHLOROQUINONE; CLINDAMYCIN; CONCANAVALIN A; ERYTHROMYCIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GLUCOSE; GLYCINE; LEUCINE; LYSINE; MACROLIDE; MYELOPEROXIDASE; PENICILLIN G; POTASSIUM FLUORIDE; QUINONE DERIVATIVE; RIFAMPICIN; ROXITHROMYCIN; SODIUM AZIDE; SODIUM CYANIDE; UNCLASSIFIED DRUG; ZYMOSAN;

ARTICLE; CELL METABOLISM; CELL VIABILITY; CENTRIFUGATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG RELEASE; DRUG RETENTION; DRUG UPTAKE; ENVIRONMENTAL TEMPERATURE; HUMAN; LYSOSOME; NEUTROPHIL; NORMAL HUMAN; PH; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTON TRANSPORT;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; HUMANS; NEUTROPHILS;

EID: 0035174343     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00430-7     Document Type: Article

References (42)

1. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children
2. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance
3. Intracellular activity of azithromycin against bacterial enteric pathogens
4. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
5. Advances in the prevention and treatment of Mycobacterium avium disease
6. C. pneumoniae and atherosclerosis: Causal or coincidental link?
7. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: Elimination of myocardial infarction with Chlamydia (ACADEMIC) study
8. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
9. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (weekly intervention with Zithromax [azithromycin] for atherosclerosis and its related disorders) trial
10. Description and status of the azithromycin and coronary events study (ACES)
11. The pharmokinetics of azithromycin in human serum and tissues
12. Correlation of the extravascular pharmacokinetics with in-vivo efficacy in models of localized infection
13. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo
14. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: Possible mechanisms of delivery and release at sites of infection
15. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia. Are we looking in the wrong place?
16. Pharmacological considerations in the emergence of resistance
17. Azithromycin concentration at the sites of pulmonary infection
18. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62,993) and its influence on ex vivo leukocyte chemiluminescence
19. Interaction of azithromycin and human phagocytic cells: Uptake of the antibiotic and the effect on the survival of ingested bacteria
20. Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus
21. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages
22. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes
23. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions
24. Isolation of lymphocytes, granulocytes, and macrophages
25. Antibiotic entry into human polymorphonuclear leukocytes
26. Effects of phagocytosis on antibiotic and nucleoside uptake by human polymorphonuclear leukocytes
27. Uptake of antibiotics by human alveolar macrophages
28. Membrane transport of clindamycin in alveolar macrophages
29. Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity
30. Entry of antibiotics into human monocytes
31. Entry of roxithromycin (RU965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes
32. Antibiotic uptake by alveolar macrophages
33. Effect of phagocyte membrane stimulation on antibiotic uptake and intracellular bactericidal activity
34. Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts
35. Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils
36. Interactions of dirithromycin with human polymorphonuclear leukocytes
37. Influence of pentoxifylline and its derivatives on antibiotic uptake and superoxide generation by human phagocytic cells
38. Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin
39. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leukocytes
40. Penetration of macrolides into human polymorphonuclear leukocytes
41. Azithromycin inhibition of intracellular Legionella micdadei
42. The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo